Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DMI 9523

Drug Profile

DMI 9523

Alternative Names: Ampion; DA-DKP; DM 9523; DMI-9523; LMWF 5A

Latest Information Update: 11 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ampio Pharmaceuticals
  • Class Antirheumatics; Dipeptides; Eye disorder therapies; Ketones; Nonsteroidal anti-inflammatories; Piperazines; Small molecules
  • Mechanism of Action Cytokine inhibitors; Immunomodulators; Inflammation mediator inhibitors; Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteoarthritis
  • Preclinical Chronic obstructive pulmonary disease
  • Research Eye disorders
  • No development reported Crohn's disease; Inflammation; Neurological disorders; Rhinitis

Most Recent Events

  • 10 Jul 2019 Ampio Pharmaceuticals announced intention to launch DMI 9523 for Osteoarthritis
  • 24 Jun 2019 Ampio Pharmaceuticals initiates the phase III AP-013 trial for Osteoarthritis in USA (Intra-articular) (NCT03988023)
  • 17 Jun 2019 Ampio Pharmaceuticals plans the phase III AP-013 trial for Osteoarthritis in USA in June 2019 (Intra-articular) (NCT03988023)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top